Affordable Access

Access to the full text

Lymphadenectomy in Ovarian Cancer: Is It Still Justified?

Authors
  • Benedetti Panici, Pierluigi1
  • Giannini, Andrea1
  • Fischetti, Margherita1
  • Lecce, Francesca1
  • Di Donato, Violante1
  • 1 “Sapienza” University of Rome, Viale del policlinico 155, Rome, 0161, Italy , Rome (Italy)
Type
Published Article
Journal
Current Oncology Reports
Publisher
Springer-Verlag
Publication Date
Feb 08, 2020
Volume
22
Issue
3
Identifiers
DOI: 10.1007/s11912-020-0883-2
Source
Springer Nature
Keywords
License
Yellow

Abstract

Purpose of ReviewThe aim of this review is to determine, in the light of recent evidences, the role of lymphadenectomy in ovarian cancer.Recent FindingsThe lymphadenectomy in ovarian neoplasms (LION) trial reports no better outcomes and higher complication and mortality rates associated with lymphadenectomy. Even if performed by expert hands, lymphadenectomy has a cost in terms of longer operative time, blood loss, higher rates of transfusions, and intensive unit care.SummaryIf on the one hand retroperitoneal staging is not correlated to survival benefits both in early and advanced ovarian cancer, on the other hand it is associated with an increased surgery-related morbidity. Surgical treatment of isolated nodal recurrences seems to be feasible and associated with survival benefits.

Report this publication

Statistics

Seen <100 times